EAST BRUNSWICK, N.J., Sept. 10, 2018 /PRNewswire/ -- Grace Therapeutics, a clinical stage biopharmaceutical company focused on rare and orphan diseases, announced today that it is scheduled to speak at the Morgan Stanley Annual Global Healthcare Conference in New York City.
Dr. Bruce Hochstadt, Chief Operating Officer, and Prashant Kohli, Head of Commercialization, will discuss the company's vision, pipeline, and commercial strategy for accelerated value creation. The presentation is scheduled for Thursday, September 13, 2018 at 4.05 p.m. Eastern Time at the Grand Hyatt New York.
About Grace Therapeutics
Grace Therapeutics, Inc. is an innovative biopharmaceutical company focused on rare and orphan diseases. Grace utilizes unique delivery technologies in developing novel product formulations to address critical unmet needs.
Grace's development pipeline consists of five product candidates focused primarily on Central Nervous System diseases. Clinical studies are ongoing for three of these late stage assets, with the remaining two advancing toward the clinic. The company is pursuing multiple commercialization options for these products for maximum value creation in its path to becoming a fully integrated commercial and marketing organization.
Headquartered in East Brunswick, New Jersey, privately held Grace has strategic agreements with pre-eminent partners in contract research, manufacturing and market development. To learn more, visit www.gtrx.com.
SOURCE Grace Therapeutics
